Skip to content

Halozyme Therapeutics HALO Tax on Share Settlement

Tax on Share Settlement at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$2.5M0.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.07M+129%
Alkermes logo
AlkermesALKS
$23.44M-18.6%
United Therapeutics logo
United TherapeuticsUTHR
$58.3M+281%
Viatris logo
ViatrisVTRS
$56.5M+92.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's tax on share settlement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's tax on share settlement?
Halozyme Therapeutics (HALO) reported tax on share settlement of $1.61M in Q1 2026.